ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck
Renal Cell Carcinoma
Cutaneous Malignant Melanoma
Lung Cancer

Melanoma trials near Barcelona, CT, ESP:

Status recently updated

Neoadjuvant Darovasertib in Primary Uveal Melanoma

This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma...

Begins enrollment this month
Enrolling
Uveal Melanoma
Procedure: Primary Local Therapy
Drug: Darovasertib

Phase 3

Ideaya Biosciences

L'Hospitalet de Llobregat, Barcelona, Spain and 59 other locations

PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients (PlugIN)

There is a lack of strategies for patients who progress after responding to PD-1/l-1 in melanoma. High expression of Nectin4 in skin and melanomas...

Enrolling
Melanoma
Drug: enfortumab vedotin
Drug: pembrolizumab

Phase 2

Grupo Español Multidisciplinar de Melanoma

Barcelona, Barcelona, Spain and 12 other locations

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma (OCULE-01)

The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma...

Enrolling
Ocular Melanoma
Uveal Melanoma
Drug: roginolisib
Drug: Investigator choice of standard therapy

Phase 2

iOnctura

Barcelona, Spain and 15 other locations

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Barcelona, Spain and 132 other locations

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

medicines (ipilimumab and nivolumab) given for the treatment of melanoma.Melanoma is a type of cancer that starts in the cells that...

Active, not recruiting
Melanoma
Drug: encorafenib
Drug: ipilimumab

Phase 2

Pfizer
Pfizer

Barcelona, Barcelona [barcelona], Spain and 23 other locations

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Active, not recruiting
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Barcelona, Spain and 110 other locations

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Barcelona, Spain and 154 other locations

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Barcelona, Spain and 71 other locations

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp with Pembrolizumab
Drug: Tebentafusp

Phase 3

Immunocore
Immunocore

Barcelona, Spain and 71 other locations

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases (ENCEFALO)

Brain metastases in patients with advanced and metastatic melanoma are a frequent complication and a significant cause of morbidity and mort...

Enrolling
Melanoma and Brain Metastases
Melanoma BRAF V600E/K Mutated
Drug: cemiplimab+fianlimab
Drug: Encorafenib + Binimetinib

Phase 2

Grupo Español Multidisciplinar de Melanoma

Barcelona, Barcelona, Spain and 18 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems